NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
Clinical Trials
10 trialsNCT04872608 2023-04-28
A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Withdrawn
NCT04316169 2022-12-23
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
Medical College of Wisconsin
Phase 1 Withdrawn
NCT04630210 2022-06-15
AteBrO
Universitaire Ziekenhuizen KU Leuven
Phase EARLY_PHASE1 Withdrawn
NCT04220476 2020-09-21
CIMER
Weill Medical College of Cornell University
Phase 2 Withdrawn
NCT02619669 2020-03-12
Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer
Dartmouth-Hitchcock Medical Center
Phase 1 Withdrawn
NCT03238703 2018-12-27
Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
Fred Hutchinson Cancer Center
Phase 4 Withdrawn
NCT01013506 2013-05-23
Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Withdrawn
NCT00403182 2012-06-01
Chemotherapy and Hormone Therapy as First-Line Therapy in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer
Technical University of Munich
Phase 3 Withdrawn
NCT00935558 2012-05-31
Dendritic Cell Based Therapy for Breast Cancer Patients
Herlev Hospital
Phase 2 Withdrawn